These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21310613)

  • 41. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
    Schroeder GM; An Y; Cai ZW; Chen XT; Clark C; Cornelius LA; Dai J; Gullo-Brown J; Gupta A; Henley B; Hunt JT; Jeyaseelan R; Kamath A; Kim K; Lippy J; Lombardo LJ; Manne V; Oppenheimer S; Sack JS; Schmidt RJ; Shen G; Stefanski K; Tokarski JS; Trainor GL; Wautlet BS; Wei D; Williams DK; Zhang Y; Zhang Y; Fargnoli J; Borzilleri RM
    J Med Chem; 2009 Mar; 52(5):1251-4. PubMed ID: 19260711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
    Kawanishi N; Sugimoto T; Shibata J; Nakamura K; Masutani K; Ikuta M; Hirai H
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5122-6. PubMed ID: 16876403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold.
    Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL
    Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
    Li Q; Chu DT; Claiborne A; Cooper CS; Lee CM; Raye K; Berst KB; Donner P; Wang W; Hasvold L; Fung A; Ma Z; Tufano M; Flamm R; Shen LL; Baranowski J; Nilius A; Alder J; Meulbroek J; Marsh K; Crowell D; Hui Y; Seif L; Melcher LM; Plattner JJ
    J Med Chem; 1996 Aug; 39(16):3070-88. PubMed ID: 8759628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.
    De Lucca GV; Liang J; Aldrich PE; Calabrese J; Cordova B; Klabe RM; Rayner MM; Chang CH
    J Med Chem; 1997 May; 40(11):1707-9. PubMed ID: 9171880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
    Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
    J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery.
    Thangapandian S; John S; Sakkiah S; Lee KW
    J Mol Graph Model; 2010 Nov; 29(3):382-95. PubMed ID: 20870437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).
    Muraoka T; Ide M; Morikami K; Irie M; Nakamura M; Miura T; Kamikawa T; Nishihara M; Kashiwagi H
    Bioorg Med Chem; 2016 Sep; 24(18):4206-4217. PubMed ID: 27448772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of dibenzo[c,f][2,7]naphthyridines as potent and selective 3-phosphoinositide-dependent kinase-1 inhibitors.
    Gopalsamy A; Shi M; Boschelli DH; Williamson R; Olland A; Hu Y; Krishnamurthy G; Han X; Arndt K; Guo B
    J Med Chem; 2007 Nov; 50(23):5547-9. PubMed ID: 17941624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
    Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
    J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1.
    Hornberger KR; Berger DM; Crew AP; Dong H; Kleinberg A; Li AH; Medeiros MR; Mulvihill MJ; Siu K; Tarrant J; Wang J; Weng F; Wilde VL; Albertella M; Bittner M; Cooke A; Gray MJ; Maresca P; May E; Meyn P; Peick W; Romashko D; Tanowitz M; Tokar B
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4517-22. PubMed ID: 23850198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.
    Antczak C; Veach DR; Ramirez CN; Minchenko MA; Shum D; Calder PA; Frattini MG; Clarkson B; Djaballah H
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6872-6. PubMed ID: 19889540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Whole-genome sequencing and cancer therapy: is too much ever enough?
    Garraway LA; Baselga J
    Cancer Discov; 2012 Sep; 2(9):766-8. PubMed ID: 22969114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
    Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
    Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
    Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenyltriazolinones as potent factor Xa inhibitors.
    Quan ML; Pinto DJ; Rossi KA; Sheriff S; Alexander RS; Amparo E; Kish K; Knabb RM; Luettgen JM; Morin P; Smallwood A; Woerner FJ; Wexler RR
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1373-7. PubMed ID: 20100660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.